Detailed explanation of the therapeutic mechanism and applicable diseases of Ustekinumab

Ustekinumab (Ustekinumab) is a targeted therapy monoclonal antibody that mainly inhibits interleukin-12 (IL-12 ) and interleukin -23 (IL-23) to play a role. IL-12 and IL-23 play key roles in the immune system and are involved in regulating inflammatory responses and activation of immune cells. Ustekinumab binds to the common p40 subunits of these two cytokines and blocks their binding to receptors, thereby inhibiting the transmission of inflammatory signals and achieving the effect of reducing the inflammatory response in immune-mediated diseases.

The therapeutic mechanism of ustekinumab enables it to show good efficacy in a variety of autoimmune diseases. It is mainly suitable for patients with moderate to severe plaque psoriasis, and can effectively reduce skin lesions and improve patients' quality of life. In addition, the drug is approved to treat psoriatic arthritis, a condition of arthritis that accompanies cutaneous psoriasis. Ustekinumab protects joint function by inhibiting inflammatory cytokines, reducing joint inflammation and destruction.

In addition to psoriasis-related diseases, ustekinumab is also used to treat inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. In these diseases, abnormal expression of IL-12 and IL-23 promotes an excessive inflammatory response in the intestine, leading to tissue damage. By targeting these two key cytokines, ustekinumab inhibits the inflammatory process, helps relieve intestinal symptoms, and promotes disease remission and maintenance.

In general, ustekinumab, as a monoclonal antibody drug targeting IL-12/23, has become an important choice for the treatment of various autoimmune diseases due to its unique mechanism of action. Patients should strictly follow the doctor's instructions when using this drug, and regularly monitor the efficacy and adverse reactions to ensure that the treatment is safe and effective. At the same time, with further research on the immune mechanism, the indications of ustekinumab are expected to continue to expand, bringing good news to more patients.

Reference materials:https://www.drugs.com/donanemab.html